In patients with CTD-PAH, the expression level of Regnase-1 is decreased, which may lead to the over-expression of inflammatory cytokines, and then promote the development of pulmonary hypertension (90). The gene discussed is ZC3H12A; the disease is pulmonary arterial hypertension.